

מכון ויצמן למדע

WEIZMANN INSTITUTE OF SCIENCE



The long-term genetic stability and individual specificity of the human gut microbiome

Document Version:

Accepted author manuscript (peer-reviewed)

Citation for published version:

Lifelines Cohort Study 2021, 'The long-term genetic stability and individual specificity of the human gut microbiome', *Cell*, vol. 184, no. 9, pp. 2302-2315.e12. <https://doi.org/10.1016/j.cell.2021.03.024>

Total number of authors:

1

Digital Object Identifier (DOI):

[10.1016/j.cell.2021.03.024](https://doi.org/10.1016/j.cell.2021.03.024)

Published In:

Cell

License:

Other

General rights

@ 2020 This manuscript version is made available under the above license via The Weizmann Institute of Science Open Access Collection is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognize and abide by the legal requirements associated with these rights.

How does open access to this work benefit you?

Let us know @ library@weizmann.ac.il

Take down policy

The Weizmann Institute of Science has made every reasonable effort to ensure that Weizmann Institute of Science content complies with copyright restrictions. If you believe that the public display of this file breaches copyright please contact library@weizmann.ac.il providing details, and we will remove access to the work immediately and investigate your claim.

1 **The long-term genetic stability and individual specificity of the**
2 **human gut microbiome**

3 Lianmin Chen ^{1,2,*}, Daoming Wang ^{1,*}, Sanzhima Garmaeva ¹, Alexander Kurilshikov
4 ¹, Arnau Vich Vila ^{1,3}, Ranko Gacesa ^{1,3}, Trishla Sinha ¹, LifeLines Cohort Study, Eran
5 Segal ^{4,5}, Rinse K. Weersma ³, Cisca Wijmenga ¹, Alexandra Zhernakova ^{1,#} and
6 Jingyuan Fu ^{1,2,6,#}

7 ¹ Department of Genetics, University Medical Center Groningen, University of
8 Groningen, Groningen, the Netherlands

9 ² Department of Pediatrics, University Medical Center Groningen, University of
10 Groningen, Groningen, the Netherlands

11 ³ Department of Gastroenterology and Hepatology, University Medical Center
12 Groningen, University of Groningen, Groningen, the Netherlands

13 ⁴ Department of Computer Science and Applied Mathematics, Weizmann Institute of
14 Science, Rehovot, Israel

15 ⁵ Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot,
16 Israel

17 ⁶Lead Contact

18 *These authors contributed equally

19 #Correspondence: j.fu@umcg.nl and sashazhernakova@gmail.com

20 **HIGHLIGHTS (max 85 characters)**

- 21 ● Gut microbial composition with higher baseline diversity is more stable over time
- 22 ● Gut microbial genetic makeup is more personal specific than composition
- 23 ● Individual-specific and temporally stable microbial profiles fingerprint the host
- 24 ● Plasma metabolites can mediate microbial impact on host health

25 **SUMMARY (max 150)**

26 By following up the gut microbiome, 51 human phenotypes and plasma levels of 1,183
27 metabolites in 338 individuals after four years, we characterize the microbial stability
28 and variation in relation to host's physiology. We made use of individual-specific and
29 temporally stable microbial profiles, including bacterial SNPs and structural variations,
30 to built a microbial fingerprinting model, which shows 82% accuracy in classifying
31 metagenomic samples four year apart. Application of our model in independent cohort
32 (HMP) provide 95% accuracy for classification of samples one year apart.
33 Simultaneously, we observed temporal changes in the abundance of multiple bacterial
34 species, metabolic pathways and structural variation, as well as strain replacement. We
35 report 258 longitudinal microbial associations with the host's phenotype and 519
36 associations with plasma metabolites. The association was enriched for cardiometabolic
37 traits, vitamin B and uremic toxins. Mediation analysis pintpoints many metabolites
38 that mediate the microbial impact on the host, providing evidence as therapeutic targets.

39 **Keywords:** gut microbiome, stability, taxonomy, pathway, SNP, copy number variation,
40 genomic deletion, metabolites, strain replacement, fingerprint

41 INTRODUCTION

42 Human guts harbor a diverse community of microbes that exhibit large between-
43 individual variations (Falony et al., 2016; Lloyd-Price et al., 2017; Rothschild et al.,
44 2018; Zhernakova et al., 2016), and cross-sectional analyses have now linked these
45 variations to human health and disease phenotypes (Chen et al., 2020a; Falony et al.,
46 2016; Rothschild et al., 2018; Vieira-Silva et al., 2020; Zhernakova et al., 2016). The
47 gut microbiota also undergoes compositional changes over the course of an individual's
48 life, either as the cause or consequence of changes in host health and disease status
49 (Chen et al., 2018; Vatanen et al., 2018; Zhou et al., 2019). Several studies have
50 assessed temporal changes in microbial taxonomical composition (Faith et al., 2013;
51 Mehta et al., 2018) and laid the foundation for targeted mechanistic investigations of
52 the consequences of host–microbiome crosstalk for health and disease, including
53 studies in early childhood (Stewart et al., 2018), early-onset type 1 and type 2 diabetes
54 (Vatanen et al., 2018; Zhou et al., 2019) and inflammatory bowel disease (Lloyd-Price
55 et al., 2019).

56 Nevertheless, several important questions about the temporal variability of the gut
57 microbiome remain unexplored. Firstly, beyond gut microbial composition, the genetic
58 makeup of microbial genomes can also undergo dynamic changes over time. Microbial
59 genomic changes due to evolution and strain replacement, such as single nucleotide
60 mutations and gain or loss of genomic regions (structural variation), implicate putative
61 mechanism for the development of human disease (Greenblum et al., 2015; Schloissnig
62 et al., 2013; Zeevi et al., 2019). Yet investigations of temporal changes in microbial
63 genetic makeup are still missing. Secondly, while cross-sectional association analyses
64 have reported numerous associations with host health and disease (Falony et al., 2016;
65 Lloyd-Price et al., 2017; Rothschild et al., 2018; Zhernakova et al., 2016), these
66 associations lack longitudinal confirmation that would allow us to assess whether
67 alterations of the gut microbiome are related to changes in host health status. Thirdly,
68 other microbial components such as antibiotic resistance and virulence factors have

69 become a major concern given the wide-scale use of antibiotics in the last decades. The
70 risk of transfer of resistance and virulence genes between microorganisms has been
71 extensively investigated due to its relevance to human health (Ochman et al., 2000).
72 However, information on the spread of antibiotic resistance and virulence genes among
73 human gut commensal microorganisms over time has not yet been reported, which
74 impedes the effective prevention and treatment of bacterial infections.

75 In this study, we present a long-term follow-up analysis of the gut microbiome in 338
76 participants of the population-based Lifelines-DEEP cohort (Tigchelaar et al., 2015), in
77 which we compared samples taken four years apart. We characterized long-term
78 temporal stability in the gut microbial composition and genetic makeup and aimed to
79 answer two types of questions: 1) Which bacterial features not only show individual
80 specificity but also temporal stable? Can we use such features as the fingerprint to
81 distinguish samples from the same individual. 2) Which bacterial features show large
82 temporal variation? Can their temporal variation be linked to the changes of host's
83 clinical phenotypes and lifestyles. To further gain biological insights, we profiled
84 plasma levels of 1183 metabolites at both time points and aimed to construct in-silico
85 causal inference of microbial impact on host's health through metabolites using
86 mediation analysis. Finally, we assessed the increase of antibiotic resistance and
87 virulence factors in the human gut microbiome, which may indicate the urgency of
88 fighting infectious disease.

89 RESULTS

90 *The LifeLines-DEEP follow-up cohort*

91 To investigate the long-term variability of the human gut microbiome, we collected
92 fecal samples from 338 individuals from the prospective, population-based Lifelines-
93 DEEP cohort taken four years apart (Tigchelaar et al., 2015) and processed these
94 samples using the same lab protocols and bioinformatic pipelines. 51 phenotypic factors
95 were assessed at both time points, including intrinsic factors (e.g. age, sex and body
96 mass index), blood cell counts, plasma metabolites (e.g. glucose, HbA1c and blood
97 lipid profile), diseases and medication usage (**Table S1**). We observe significant
98 temporal changes for 19 phenotypic factors four years apart at $FDR < 0.05$ (**Figure S1**,
99 **Table S1**). For instance, significant increases were observed for plasma levels of
100 creatinine ($P_{\text{Paired Wilcoxon}} = 2.5 \times 10^{-50}$), systolic blood pressure ($P_{\text{Paired Wilcoxon}} = 3.6 \times 10^{-26}$),
101 and blood basophil granulocytes cell counts ($P_{\text{Paired Wilcoxon}} = 8.2 \times 10^{-39}$) (**Figure S1**,
102 **Table S1**). We also observed changes in lifestyle, diseases and medication usage (**Table**
103 **S1**). For example, compared to the baseline, the number of smokers was reduced by
104 4.5%, and 17 participants started using proton pump inhibitors (PPI), while 6 stopped.

105 *Temporal changes in the gut microbial diversity and composition*

106 To characterize the stability of the gut microbiome over time, we first investigated
107 microbial composition and diversity. Compared to baseline, we observed a significant
108 increase in the alpha-diversity (Shannon index based on species, $P_{\text{Paired Wilcoxon}} = 2.4 \times 10^{-7}$,
109 **Figure 1A**), as well as a moderate variation in microbial taxonomical and functional
110 composition ($P_{\text{PCo1 Paired Wilcoxon}} > 0.082$ and $P_{\text{PCo2 Paired Wilcoxon}} < 1.6 \times 10^{-5}$ for both species
111 and pathway, **Figure S2**). The differences in overall microbial taxonomical and
112 functional composition were larger between individuals than within-individuals ($P_{\text{Wilcoxon}} < 1 \times 10^{-4}$,
113 **Figure 1B&C**), indicating that even after four years an individual's gut
114 microbial composition is more similar to itself than to those of other people.
115 Interestingly, within-individual differences in gut microbial composition were smaller
116 in participants with a higher alpha-diversity at baseline ($r_{\text{Spearman}} = -0.21$, $P = 1.5 \times 10^{-4}$,

117 **Figure 1D**), supporting the hypothesis that a diverse microbial communities tend to be
118 more stable (Coyte et al., 2015).

119 When comparing individual microbial species and pathways, the relative abundance of
120 59.9% species (94 out of 157) and 44.3% pathways (152 out of 343) showed significant
121 changes at FDR<0.05 (paired Wilcoxon test, **Table S2a&b**). Species belonging to the
122 same genera often showed consistent changes in direction, e.g. the relative abundance
123 of seven *Bifidobacterium* species all decreased significantly, while the abundances of
124 the majority of *Alistipes* species (7 out of 8) increased (**Table S2a**). These changes may
125 partially be due to the age effect. For instance, several *Bifidobacterium* species
126 including *B. adolescentis*, *B. bifidum* and *B. longum* have been observed to be
127 negatively associated with age (Zhernakova et al., 2016).

128 ***Microbial genetic stability differs substantially across species***

129 Microbial genetic makeup may also change over time, e.g. due to mutagenesis and
130 strain replacement as a consequence of selective pressure. Characterization of the stable
131 and changeable genetic components of the gut microbiome over a long time-course is
132 important for further understanding the importance of microbial strains alterations with
133 respect to host phenotypic changes. Here, we characterized within-individual temporal
134 microbial genetic changes by comparing both single nucleotide polymorphism (SNP)
135 haplotypes (Truong et al., 2017) and genomic structural variants (SVs) (Zeevi et al.,
136 2019). SNP haplotype differences were characterized for 37 species that were present
137 in at least 5 paired samples from both time points (**Figure 2A, Table S2c**). We also
138 identified 6,130 SVs, including 4,333 deletion SVs (absence of genomic regions) and
139 1,797 variable SVs (genomic regions with variable copy numbers) from 41 microbial
140 species in at least 5 paired samples (**Figure 2B, Table S2d**). For 23 species, both strain
141 SNP haplotype and SV information were available (**Figure 2A&B**).

142 We observed that within-individual genetic changes in terms of both SNP haplotypes
143 and SVs were significantly smaller than the differences observed between different

144 individuals (**Figure 2A&B, Table S2c&d**). The species that showed large temporal
145 changes in their SNP haplotypes include *Ruminococcus torques*, *Streptococcus*
146 *parasanguinis* and *Faecalibacterium prausnitzii*, while *Bifidobacterium angulatum*,
147 *Methanobrevibacter smithii* and *Alistipes putredinis* showed relatively low genetic
148 variability ($P_{\text{Wilcoxon}} < 0.05$, **Figure 2A**). A consistent trend in genetic stabilities in terms
149 of SNP profile was observed in 43 healthy participants with fecal microbiome data
150 available one year apart from the Human Microbiome Project (HMP) (**Figure 2C**)
151 (Schloissnig et al., 2013). Compared to the HMP cohort, the genetic difference of
152 unstable species were larger in the LLD cohort potentially due to a longer time duration
153 (**Figure 2D-F**). This observation further supports the genetic instability of these species
154 over time.

155 Temporal variability in SNP haplotypes and SVs also showed consistency (**Figure S3**),
156 suggesting that the microbial genetic stability of some species can be seen at different
157 genetic variation levels. For example, several species with highly variable SNP
158 haplotypes over time, such as *R. torques* and *F. prausnitzii*, also showed a high degree
159 of changes in their SVs, while some species, such as *M. smithii*, showed high stability
160 of both SNP haplotypes and within-individual SVs variability (**Figure 2A&B**).

161 Interestingly, these genetic unstable species have often been reported to be related to
162 human health and disease. For instance, previous studies have shown a higher
163 abundance of *R. torques* in patients with Crohn's disease (Joossens et al., 2011), a higher
164 level of *S. parasanguinis* in patients with intestinal infection (Vacca, 2017), and a lower
165 level of *F. prausnitzii* in patients with inflammatory bowel disease (Munukka et al.,
166 2017; Vich Vila et al., 2018). Notably, within-individual changes in microbial genetic
167 makeup did not correlate with changes in abundance (**Figure S4**), suggesting that
168 microbial genetic variability provides a new layer of information that is independent of
169 microbial abundance. Furthermore, the observed temporal changes in genetic make-up
170 can be also due to strain replacement. For instance, we could detect distinct strains
171 based on SNP profiles in *R. torques*, *F. prausnitzii*, *S. parasanguinis*, *Ruminococcus*

172 *obeum* and *Eubacterium rectale* (**Figure S5**). For instance, we observed two distinct
173 strain clusters in *F. prausnitzii* (**Figure 3A, Figure S5**) and found that strain
174 replacement happened in 37 participants (**Figure 3B**).

175 Taken together, these results illustrate that within-individual variations in both
176 microbial composition and genomes can be seen four years apart, but within-individual
177 similarity of microbiome compositional and genetic profiles is greater than between-
178 individual similarity. The observed stable and variable microbial compositional and
179 genetic components can have different implications: the individually stable microbial
180 components might be used to identify their host, while the variable microbial
181 components might reveal their clinical relevance in relation to phenotypic changes.

182 ***Microbial genetic makeups show individuality that serve as host fingerprint***

183 We observed that some species, such as *M. smithii*, showed large between-individual
184 variability but small within-individual variability in their genetic makeup (**Figure 2A**).
185 Per 100 base pairs (bp) of the species-specific regions, *M. smithii* had an on average
186 0.11 bp difference between two samples from the same individual but an average 2.78
187 bp difference between different individuals ($P_{\text{Wilcoxon test}}=3.6 \times 10^{-64}$, **Figure 2A, Table**
188 **S2c**). This led us to evaluate the possibility of using microbial genetic and
189 compositional profiles to identify samples from the same individuals. We could
190 generate the SNP haplotype profiles of *M. smithii* for 100 paired samples. Based on the
191 distance of the *M. smithii* SNP profiles, we could correctly link 94 paired individuals,
192 resulting in an accuracy of 94% (**Figure S6A**). Another example was the SNP profile
193 of *Phascolarctobacterium succinatutens* that can classify 41 paired samples with 88%
194 of accuracy (**Figure S6B**). Notably, sample classification based on microbial
195 composition and pathway profile could only result in 12% and 5% accuracy,
196 respectively (**Table S3**). Our data prove that microbial genetic profiles can be applied
197 as an individual fingerprint and that genetic profiles of the gut microbiome greatly
198 outperform species and pathway abundance profiles in individual identification.

199 Due to low abundance and insufficient read coverage in some samples, SNP haplotype
200 profiles like *M. smithii* could only be generated for 100 out of 338 paired samples,
201 which prohibits the use of the genetic profile of one single species as a host fingerprint.
202 This limitation inspired us to combine multiple microbial genetic and composition
203 (both species and pathway abundances) distance matrices for a broader application. We
204 applied stepwise forward selection to optimize the combination of different numbers of
205 distance matrices in 60% of randomly selected individuals and validated the individual
206 recognition abilities in the remaining 40% of individuals. The resampling and feature
207 selection were repeated 10 times (**Figure S7**). The combination of all 71 distance
208 matrices (**Table S3**) resulted in up to 85% classification accuracy (**Figure 4A**), and an
209 optimal model combining the top 30 distance matrices yielded 82% classification
210 accuracy (**Figure 4B**). This optimal model includes SNP profiles of 13 species, deletion
211 SV profiles of 11 species, variable SV profiles of 5 species and the Bray-Curtis
212 dissimilarity of species abundance (**Figure S8**). We also conducted the specificity and
213 sensitivity analyses in sample classification. The total area under curve (AUC) was 95%
214 (**Figure 3C**) and we reached the optimal 99% of specificity and 88% of sensitivity at
215 the distance cutoff 0.46 (**Figure 3D**). At this cutoff, we obtained 298 paired samples
216 with 93% of accuracy.

217 We further applied our microbial fingerprint model in the longitudinal sample collection
218 of 43 individuals in the HMP cohort. Our model resulted in 100% of accuracy for 41
219 out of 43 paired samples at the distance cutoff 0.46 (**Figure 3B**) and 95% of accuracy
220 in the total set of 43 pairs. The accuracy is much higher than the previously reported
221 30% accuracy based on microbial abundance only (Franzosa et al., 2015). This result
222 has confirmed the robustness of our microbial fingerprint method, suggesting its broad
223 application in longitudinal microbiome studies.

224 ***Microbial abundance and genomic changes associated with host phenotypes***

225 To examine the role of the gut microbiota in host health, we explored the associations

226 between microbial compositional and genomic changes and host phenotypic changes.
227 We performed two-step analyses to reveal microbial associations to host phenotypes
228 using longitudinal data. First, we performed joint association analyses between
229 microbial features and 27 host phenotypic factors that were highly prevalent between
230 the two time points (**Table S1**) by using mixed models and including age, sex and
231 sampling time as covariates. Next, for associations identified at $FDR < 0.05$, we
232 conducted regression analysis on temporal differences, i.e. associations between
233 microbial changes and host phenotypic changes over time (delta association). The
234 identified 258 associations (involving 225 microbial features and 39 phenotypes) that
235 were significant at $FDR < 0.05$ in the joint association analysis and also significant at
236 $P < 0.05$ for the delta association analysis with a consistent direction of effect. These
237 included 113 associations with species and pathway abundances and 145 associations
238 with microbial SVs (**Figure 5A, Table S4a**).

239 In line with the significant changes in blood pressure and other cardiometabolic
240 phenotypes four years apart, we detected multiple associations to the temporal changes
241 of the gut microbiome (**Table S4a**). The top associations included a positive association
242 between systolic blood pressure and the abundance *Lachnospiraceae bacterium*
243 ($\beta_{\text{delta}} = 0.24$, $P_{\text{delta}} = 1.1 \times 10^{-5}$, **Figure 5B**) and a negative association between
244 glycated hemoglobin (HbA1c) and flavin biosynthesis pathway ($\beta_{\text{delta}} = -0.22$, $P_{\text{delta}} =$
245 4.9×10^{-5} , **Figure 5C**). We also observed that the prevalence of heart rhythm problems
246 associated with the absence of a genomic region (927-928kb) in *Collinsella sp* that
247 encodes the branched-chain amino acids transport system ($P_{\text{Fisher exact test}} = 5.0 \times 10^{-4}$,
248 **Figure 5E**). Besides, we observed association of temporal changes in microbial SVs
249 with host immune phenotypes. For instance, a variable SV (3019-3020kb) in *Blautia*
250 *obeum* that contains virulence protein E and chloramphenicol resistance genes
251 negatively associated with the change of blood lymphocyte cell counts ($\beta_{\text{delta}} = -0.29$,
252 $P_{\text{delta}} = 6.5 \times 10^{-4}$, **Figure 5D**).

253 ***Microbial abundance and genomic changes associated with plasma metabolites***

254 To further understand the potential mechanisms by which the gut microbiota could
255 drive host pathophysiology, we hypothesized that metabolites are an important class of
256 molecules that is involved in host-microbe interaction. By profiling plasma levels of
257 1,183 metabolites in both timepoints with untargeted LC-MS, we observed that 27% of
258 metabolites showed significant difference between two timepoints at $FDR < 0.05$ (Paired
259 Wilcoxon, **Table S2e**).

260 We first checked whether plasma metabolites showed difference in participants with
261 distinct microbial strains of five genetical unstable species (**Figure S5**), and if so,
262 whether strain replacements of these species were related to changes in plasma
263 metabolites. In total, 64 associations were observed between 63 metabolites and strain
264 clusters of five species (**Table S4b**). For example, we identified two distinct strain
265 clusters of *F. prausnitzii* in 292 paired samples (**Figure 3A**), which associated with 15
266 metabolites. The top associations were observed for licorisoflavan A, pyrrole and p-
267 cresol sulfate, which abundances were significantly lower in the individuals with *F.*
268 *prausnitzii* strain cluster2. Consistently, we observed that the abundance of these
269 metabolites decreased in 24 individuals where *F. prausnitzii* swiftd from strain cluster1
270 to cluster2, while their metabolite levels increased in 13 individuals where *F. prausnitzii*
271 swiftd from strain cluster2 to cluster1(**Figure 3C-E**). This result implicates that
272 different microbial strains may have different functions that influence host metabolism.

273 Apart from it, temporal changes in microbial abundance and SVs may also relevant for
274 host metabolic changes. In total, 455 significant associations were detected between
275 122 microbial features (species and pathway abundances, dSVs and vSVs) and 81
276 metabolites ($FDR_{\text{joint}} < 0.05$ and $P_{\text{delta}} < 0.05$, **Figure 6A**, **Table S4c**), including 273
277 associations with microbial abundance and 182 associations with microbial SVs.
278 Interestingly, various metabolites that associated with microbiome are known to be
279 related to the gut microbiome. For instance, we detected 38 microbial associations to
280 plasma thiamine levels, a vitamin (B1) produced by gut microbes and its deficiency
281 affecting the cardiovascular system and inducing a fast heart rate (DiNicolantonio et al.,

282 2013). The top microbial associations to thiamine include species *Alistipes senegalensis*
283 ($\beta_{\text{delta}} = 0.20$, $P_{\text{delta}} = 4.1 \times 10^{-4}$, **Figure 6B**), *Bacteroidales bacterium* ($\beta_{\text{delta}} = 0.23$,
284 $P_{\text{delta}} = 5.2 \times 10^{-5}$), and TCA cycle pathway ($\beta_{\text{delta}} = 0.23$, $P_{\text{delta}} = 7.2 \times 10^{-5}$) (**Table S4c**).
285 Notably, genome of *Alistipes senegalensis* contains genes responsible for thiamine
286 biosynthesis (Mishra et al., 2012).

287 Another interesting category of metabolites are protein-bound uremic toxins, which are
288 related to microbial metabolism of amino acids and have been associated with various
289 chronic diseases (Wang and Zhao, 2018). We have characterized plasma levels of 58
290 uremic toxins from metabolite categories of indoxyl sulfate, p-cresyl sulfate, phenyl
291 sulfate, phenylacetic acid and hippuric acid (Wang and Zhao, 2018), and observed a
292 significant enrichment for microbial associations, i.e., a total of 97 associations for 16
293 uremic toxins (Fisher's exact test $P = 1.7 \times 10^{-21}$) (**Figure 6A, Table S4c**). The most
294 associated uremic toxins included p-cresol (24 associations), p-cresol sulfate (20
295 associations) and hippuric acid (16 associations) (**Table S4c**). p-cresol sulfate is a
296 microbiota-driven metabolite that contributes to many biological and biochemical
297 effects, such as albuminuria in diabetic kidney disease (Kikuchi et al., 2019). The top
298 association to p-cresol sulfate was *Bacteroidales bacterium ph8* ($\beta_{\text{delta}} = 0.21$, $P_{\text{delta}} =$
299 1.9×10^{-4} , **Figure 6C**), a gut microbial species with limited information available yet.
300 Notably, 22.6% of (103 out of 455) microbial associations with metabolites were related
301 to vSVs of *Blautia wexlerae* (**Figure 6A**). Among them, 27 associations were related
302 to different uremic toxins, particularly to hippuric acid (**Figure 6D**), an acyl glycine
303 formed from the conjugation of benzoic acid with glycine and associated with
304 phenylketonuria, propionic acidemia and tyrosinemia (Duranton et al., 2012).
305 Intriguingly, these vSV regions that encode various membrane transporters, amino
306 acid kinases, urease accessory protein and protein binding genes (**Table S5**).

307 ***Microbiome contributed to host phenotypic changes through its metabolites***

308 For 225 microbial features associated with clinical phenotypes and 122 associations to
309 metabolites, 29 microbial features were associated with both clinical phenotypes and

310 metabolites (**Figure 7A**). We explored whether these metabolites can mediate the
311 microbial impact on host's phenotypes. By using bi-directional mediation analysis, 21
312 mediation relationships were established ($FDR_{\text{mediation}} < 0.05$ and $P_{\text{inverse mediation}} > 0.05$,
313 **Figure 7B, Table S4d**). The identified mediation effects were mostly related to
314 microbial impact on blood pressure via thiamine and acetyl-N-formyl-5-
315 methoxykynurenamine (AFMK). The impact of thiamine on cardiometabolic health has
316 been well documented and a randomized controlled trial has showed that thiamine can
317 reduce diastolic blood pressure (Alaei-Shahmiri et al., 2015). AFMK is the degradation
318 metabolite of melatonin, which contributes to blood pressure reduction by inhibiting
319 the synthesis of prostaglandin (Mayo et al., 2005; Rezzani et al., 2010). Our mediation
320 analysis suggested that various bacterial pathways may contribute to these effects. For
321 instance, microbial sulfate reduction pathway can lower diastolic blood pressure
322 through increasing the plasma level of thiamine levels (21%, $P_{\text{mediation}} = 6.0 \times 10^{-3}$, **Figure**
323 **7C**) and bacterial lipopolysaccharides biosynthesis may lead to a decrease of systolic
324 blood pressure through affecting plasma level of AFMK (16%, $P_{\text{mediation}} = 6.0 \times 10^{-3}$,
325 **Figure 7D**). Metabolic products like cysteine from bacterial sulfate reduction pathway
326 is essential for bacterial thiamine (vitamin B1) biosynthesis (Begley, 1996), and
327 lipopolysaccharides can activate melatonin oxidized into AFMK (Silva et al., 2004).

328 We also identified several mediation effects of metabolites on microbial impact on
329 plasma lipids and glucose levels (**Figure 7B**). An interesting one is tyrosol 4-sulfate, an
330 uremic toxin that mediates the effect of a vSV in *Ruminococcus sp* (300 to 305 kb) on
331 plasma levels of LDL (17%, $P_{\text{mediation}} = 0.017$, **Figure 7E**). This vSV contains an ATPase
332 that responsible for metabolites transmembrane transport (Aguilar-Barajas et al., 2011).

333 ***Significant increase of microbial antibiotic resistance***

334 The increase of antibiotic resistance can pose a great burden in fighting infectious
335 diseases, while the virulence factors are essential for the commensal microbiota to
336 maintain colonization niche and evade the host's immune response. We further
337 systematically characterized and compared the abundances of 29 antibiotic resistance

338 genes and 59 virulence genes over time. We observed a significant increase in the total
339 antibiotic resistance gene load ($P=1.1 \times 10^{-9}$) and a decrease in the total number of
340 virulence genes ($P=5.1 \times 10^{-4}$) (**Figure 8A&B**). At the individual gene level, 55.17% (16
341 out of 29) of antibiotic resistance genes and 18.64% (11 out of 59) of virulence genes
342 showed a significant difference ($FDR < 0.05$) between time points (**Table S2f&g**).
343 Specifically, 15 out of 16 antibiotic resistance genes showed an increase in their
344 abundance, with the highest change observed for tetracycline resistance genes (**Figure**
345 **S9**), such as tetracycline resistance protein Q (TetQ) that is widely distributed in
346 *Bacteroides* species (Veloo et al., 2019). In line with this, the increase of tetracycline
347 resistance gene abundance was associated with the increased abundance of multiple
348 *Bacteroides* species (e.g. *B. vulgatus*, *B. uniformis* and *B. ovatus*, **Figure 8C**, **Table**
349 **S4e**) whose abundance also increased in the follow-up (**Table S2a**).

350 Through antibiotic prescription in the Netherlands remains the lowest in the Europe,
351 tetracycline, aminoglycoside and lincosamide are among the top broad spectrum
352 veterinary antibiotics (Havelaar et al., 2017), which may contribute to the increased
353 microbial antibiotic resistance in humans (Aslam et al., 2018). We thus examined the
354 correlation of baseline meat intake with the abundance changes of microbial antibiotic
355 resistance genes and found positive associations with aminoglycoside ($r_{\text{Spearman}} = 0.18$,
356 $P = 9.2 \times 10^{-4}$) and lincosamide resistance ($r_{\text{Spearman}} = 0.15$, $P = 5.5 \times 10^{-3}$) (**Figure 8D&E**,
357 **Table S4f**). These observations raise concerns about antibiotic usage in farming, which
358 may contribute to the spread of microbial antibiotic resistance in the human gut
359 ecosystem.

360 **DISCUSSION**

361 Over the past years, numerous associations between a disrupted microbiota and diseases,
362 for example gastrointestinal and cardiometabolic diseases, have been observed in large
363 cross-sectional studies (Chen et al., 2020a; Chen et al., 2020b; Falony et al., 2016;
364 Rothschild et al., 2018; Vieira-Silva et al., 2020; Zhernakova et al., 2016). However,
365 the key to understanding the role of a disrupted microbiota in human diseases is to

366 answer how stable the microbiota is and whether within-individual microbial changes
367 can be linked to changes in host health status. We therefore systematically characterized
368 the microbial changes at both compositional and genomic level at two time points four
369 years apart in 338 individuals from the Lifelines-DEEP cohort. We observed that the
370 gut microbiome to some extent showed long-term within-individual stability in both
371 microbial abundance and microbial genome. Particularly, we found that the genetic
372 makeup of microbes shows individuality that can be used as a fingerprint to distinguish
373 metagenomic samples belonging to the same individual. In addition, the longitudinal
374 association analysis between the changes of gut microbiome, host phenotypic, as well
375 as human plasma metabolites have provided in-silico causal relationships and putative
376 mechanistic insights regarding the importance of the gut microbiome on human health.
377 Finally, we observed that increased microbial antibiotic resistance in the human gut
378 microbiome was associated with meat consumption.

379 Previous investigations on short-term (within one year) temporal stability of microbial
380 composition and genetic makeup in adults revealed that metagenomic samples obtained
381 from the same individual are more similar to one another than to those from different
382 individuals (Garud et al., 2019; Mehta et al., 2018). Large-scale characterization of the
383 long-term (four years apart) stability of the gut microbiome in a present study extended
384 this observation. In addition, we found that within-individual differences in gut
385 microbial composition were smaller in participants who had a higher alpha-diversity at
386 baseline, supporting the hypothesis that the microbial communities with higher
387 diversity tend to be more stable over time (Coyte et al., 2015).

388 We also observed that genetic stability of gut microbes vary substantially across
389 different species, and a set of species from, but not limited to genus *Bacteroides*,
390 *Bifidobacterium*, *Methanobrevibacter* and *Phascolarctobacterium* showed relatively
391 high within-individual stability over a long period of time. Notably, previous study
392 showed that some of these species, such as *Bacteroides* and *Bifidobacterium* species
393 are colonized at early life (Yassour et al., 2018) and showed high genetic stability in

394 childhood (Vatanen et al., 2019). These data suggests that each person is likely to have
395 individual-specific microbial genetic components that are distinct from those of others,
396 and may span from childhood to adulthood. The gut microbial genetic profile can
397 therefore serve as a host fingerprint to uniquely distinguish stool samples that belong
398 to the same host. In this study, we constructed a novel microbial finger printing model
399 that combines 30 microbial features, including microbial composition, SNP profiles of
400 13 species and structural variation of 16 species. Our model has the accuracy of sample
401 identification to 82% in the Lifelines-DEEP samples that were taken four years apart.
402 By applying our model to the HMP samples up to one year apart, our model resulted in
403 95% of accuracy, significantly outperforming the previous method based on microbial
404 composition only, which resulted in only 30% accuracy (Franzosa et al., 2015). These
405 results demonstrate the potential application of our method in distinguishing sample
406 mix up, but also raise potential privacy concerns for subjects enrolled in human
407 microbiome research projects.

408 Characterization of the long-term changes of the gut microbiome is crucial for
409 understanding the role of the gut microbiome in chronic disease, the diseases being of
410 long duration and generally slow progression. Differential microbial abundances have
411 been characterized for around half of microbial species and pathways, and within-
412 individual changes in microbial genetic makeup have also been observed. Interestingly,
413 the bacterial SNP haplotype and SV changes did not associate with abundance changes,
414 which reveals a potential new layer of information about the microbiome's contribution
415 to host health that is independent of abundance alterations. Our study reported a total
416 of 258 associations between microbial changes with phenotypic changes over time.
417 Moreover, by assessing the plasma level of 1,183 metabolites at both time points, we
418 reported 519 associations between microbial changes with metabolic changes,
419 including 273 associations with abundance of species and metabolic pathways, 64
420 associations with strain replacement, and 182 associations with alternation in structural
421 variation. In contrast to previous studies that only focused on microbial abundance

422 associations to host phenotypes (Lloyd-Price et al., 2019; Vatanen et al., 2018; Zhou et
423 al., 2019), the microbial genetic associations that connect genomic variation with
424 genetically encoded function to phenotypic changes can provide putative mechanistic
425 information. We noticed that genetically unstable species (e.g. *R. torques*, *S.*
426 *parasanguinis* and *F. prausnitzii*) have been associated with various human diseases
427 (Joossens et al., 2011; Ray et al., 2014; Vacca, 2017; Zhernakova et al., 2016). *F.*
428 *prausnitzii* can support mucosal immune homeostasis (Hornef and Pabst, 2016),
429 which has been mostly linked to its capacity of butyrate production (Miquel et al., 2013).
430 However, our data shows that the higher increase in a variable SV of *F. prausnitzii* was
431 associated with the lower increase in the number of lymphocytes cells. This SV region
432 encodes multiple toxin degradation genes. Interestingly, we also observed *F.*
433 *prausnitzii* strain replacement in 37 individuals and established many associations with
434 plasma metabolites, including Licorisolfovan A and p-cresol sulfate from the class of
435 isoflavonoids and uremic toxins that affect host's immunity. Thereby our data together
436 suggests novel mechanisms underlying the role of *F. prausnitzii* in host's immunity.

437 Notably, metabolite associations to the gut microbiome were significantly enriched for
438 uremic toxins and thiamine (vitamin B1). Uremic toxins are derived by gut microbiota
439 from dietary protein and the accumulation of uremic toxins can induce chronic sterile
440 inflammation, which in turn increases the risk of kidney and cardiometabolic diseases
441 (Solomon et al., 2010). We characterized 58 protein-binding uremic toxins and detected
442 97 associations for 16 uremic toxins. One of the mostly associated uremic toxins
443 is hippuric acid, a cardiometabolic risk related metabolite that can significantly
444 contribute to the prediction of weight gaining (Yu et al., 2018; Zhao et al., 2016). We
445 observed several novel microbial associations with hippuric acid, such as the
446 associations between *B. wexlerae* SVs and hippuric acid. These *B. wexlerae* SVs were
447 also associated with BMI, implicating *B. wexlerae* may contribute to metabolic disorder
448 potentially through hippuric acid metabolism.

449 Vitamin B1 production is dependent on the gut microbiome, and the deficiency can

450 influence the cardiovascular system (DiNicolantonio et al., 2013). Among microbial
451 associations to vitamin B1, the top association was related to *Akkermansia muciniphila*
452 abundance, a well-known beneficial microbe that controls gut barrier function and
453 homeostatic functions (Everard et al., 2013). Our mediation analysis identified 21
454 relationships that the metabolites can mediate the microbial impact on host phenotype,
455 particularly for cardiometabolic traits. With this analysis, we further revealed that *A.*
456 *muciniphila* may influence blood pressure through vitamin B1 production, a rationale
457 for the development of a treatment that uses this human mucus colonizer for the
458 prevention of hypertension. All together, our longitudinal microbial association and
459 mediation analyses on host phenotypes and plasma metabolites provided novel
460 functional insights and putative causality regarding the role of the gut microbiome in
461 human health and disease.

462 Furthermore, our study provide evidence that antibiotics used in animal husbandry can
463 result in the increase of the antibiotic resistance genes in the human gut microbome.
464 Regulating and promoting the appropriate use of veterinary antibiotics should be
465 considered by public health policy makers.

466 **Limitations of Study**

467 We acknowledge several limitations in our study. Our study sampled fecal samples four
468 year apart in 338 samples. To date, it is the longitudinal microbiome study with the
469 longest duration and largest sample size. We systematically investigated the
470 compositional and genetic variation over time and link the microbial changes to
471 phenotypic changes. However, our sample size was still limited. Many of our findings
472 need further replication in independent cohorts with longer duration and larger sample
473 size. For example, we observed that gut microbial composition with higher baseline
474 diversity is more stable over time. The observed effect was modest and needs to be
475 further validated. Moreover, the Lifelines-DEEP cohort is comprised of participants
476 from northern area of the Netherlands and with only Dutch ethnicity. It is possible that
477 the reported results are biased towards a region-specific microbial background due to

478 host's genetics and local environmental exposures. Despite the possible bias, the
479 performance of our novel microbial finger printing model has been successfully
480 validated in the HMP cohort. Furthermore, the reported longitudinal association are not
481 a proof of causation even though we applied casual mediation analysis to refer in-sillico
482 causality. We primarily focused on biologically plausible mechanisms by intergrating
483 longitudinal metabolism dataset and provides mechanistic hypotheses that pinpoint to
484 specific microbial genetics and function but also demonstrate which metabolites are
485 likely to mediate the impact of the gut microbiome on the host's phenotype.
486 Experimental validation is warranted.

487 **ACKNOWLEDGEMENTS**

488 We thank the participants and staff of the LifeLines-DEEP cohort for their collaboration.
489 We thank J. Dekens and J. Arends for management and technical support and K. Mc
490 Intyre for English editing. This project was funded by the Netherlands Heart
491 Foundation (IN-CONTROL CVON grant 2012-03 and 2018-27 to A.Z. and J.F.); the
492 NWO Gravitation Netherlands Organ-on-Chip Initiative to J.F. and C.W., the NWO
493 Gravitation Exposome-NL (024.004.017) to J.F., A.K., and A.Z.; the Netherlands
494 Organization for Scientific Research (NWO) (NWO-VIDI 864.13.013 to J.F., NWO-
495 VIDI 016.178.056 to A.Z., NWO-VIDI 016.136.308 to R.K.W. and NWO Spinoza
496 Prize SPI 92-266 to C.W.); the European Research Council (ERC) (FP7/2007-
497 2013/ERC Advanced Grant 2012-322698 to C.W. and ERC Starting Grant 715772 to
498 A.Z.); the RuG Investment Agenda Grant Personalized Health to C.W.; and the
499 Foundation De Cock-Hadders grant (20:20-13) to L.C. L.C. also holds a joint
500 fellowship from the University Medical Centre Groningen and China Scholarship
501 Council (CSC201708320268). D.W. holds a fellowship from the China Scholarship
502 Council (CSC201904910478). S.G. holds a fellowship from the Graduate School of
503 Medical Sciences, University of Groningen. R.K.W. is supported by the Seerave
504 Foundation and the Dutch Digestive Foundation (16-14). The funders had no role in the
505 study design, data collection and analysis, decision to publish, or preparation of the

506 manuscript.

507 **AUTHOR CONTRIBUTIONS**

508 C.W., A.Z. and J.F. conceptualized and managed the study. L.C., W.D., S.G., A.K.,

509 A.V.V., R.G. and T.S. generated the data. L.C., W.D., S.G. and A.K. analyzed the data.

510 L.C., D.W., S.G. and J.F. drafted the manuscript. L.C., W.D., S.G., A.K., A.V.V., R.G.,


511 T.S., E.S., R.K.W., C.W., A.Z. and J.F. reviewed and edited the manuscript.

512 **COMPETING INTERESTS**


513 The authors declare no competing interests.

514 **FIGURE LEGENDS**

515 **Figure 1. Long-term stability of the gut microbiome composition.** **A.** The gut
 516 microbial alpha diversity (Shannon index) increased after four years. **B & C.** Within-
 517 individual changes in microbial species and pathway composition were lower than
 518 between-individual differences. **D.** Temporal changes in microbial composition
 519 (species-level Bray-Curtis dissimilarity) were negatively associated with baseline alpha
 520 diversity.




522 **Figure 2. Long-term stability of microbial species SNP haplotypes and structural**
 523 **variants.** **A.** Within- and between-individual differences in the single nucleotide
 524 polymorphism (SNP) haplotypes of dominant strains of microbial species. Numbers
 525 follow species names indicate the number of paired samples for which SNP haplotype
 526 profiles are available four years apart. **B.** Within- and between-individual difference in
 527 the deletion and variable structural variants (SVs) of microbial strains. Numbers follow
 528 species names indicate the number of paired samples for which SVs profiles are
 529 available four years apart. **C.** Comparison of within-individual microbial species SNP
 530 haplotype difference between the LLD (four years apart) and the HMP (one year apart).
 531 Each dot represents one species. Dots marked in orange represent SNP haplotype
 532 differences show difference between the LLD and the HMP at FDR < 0.05 (Wilcoxon
 533 test). **D, E & F.** Within-individual SNP haplotype differences in genetical unstable
 534 *Ruminococcus torques*, *Faecalibacterium prausnitzii* and *Eubacterium rectale* show
 535 difference between the LLD and the HMP.



536


537 **Figure 3. *Faecalibacterium prausnitzii* strain replacement associated with plasma**
538 **metabolite changes. A.** Two distinct *F. prausnitzii* strain clusters based on its SNP
539 haplotype profile. **B.** Within-individual *F. prausnitzii* strain switches four years apart.
540 **C, D & E.** Plasma levels of licoriso flavan A, 1,2,5-Trimethyl-1H-pyrrole and p-cresol
541 sulfate showed difference between distinct *F. prausnitzii* strains, and *F. prausnitzii* strain
542 switches associated with changes of these metabolites.



543

544 **Figure 4. Performance of the gut microbiome in fingerprinting its human host. A.**
 545 The combination of all microbial genetic and compositional profiles resulted in up to
 546 85% accuracy in distinguishing 676 metagenomic samples from 338 individuals four
 547 years apart. A combination of 30 microbial genetic and compositional profiles resulted
 548 in an accuracy of 82% in the LLD. **B.** The combination of 30 microbial genetic and
 549 compositional profiles resulted in an accuracy of 95% in the HMP cohort that involved
 550 43 participants with metagenomics available one year apart. **C.** A combination of 30
 551 microbial genetic and compositional profiles resulted in 95% and 99% AUCs for the
 552 LLD and the HMP individual classification in ROC analysis, respectively. **D.** The
 553 distribution of within- and between-individual distances in the combined distance
 554 matrices. At a cutoff of 0.46, the classification performance in terms of both specificity
 555 and sensitivity reached optimally.


556




557 **Figure 5. Association of microbial temporal changes with host phenotypic changes.**

558 **A.** Summary of microbial associations to phenotypes. A total of 258 associations were
 559 not only significant at $FDR < 0.05$ for the joint association analysis, but also significant
 560 at $P < 0.05$ for the association analysis of temporal changes, with the same effect
 561 direction of both analyses. These include 113 associations to species and pathway
 562 abundances and 145 associations to microbial SVs. **B.** Positive association between
 563 systolic blood pressure and *Lachnospiraceae bacterium* abundance changes. **C.**
 564 Negative association between plasma HbA1c and fungi flavin biosynthesis pathway
 565 abundance changes. **D.** Increased *Blautia obeum* vSV (3019-3020 kb) variabilities
 566 associated with the decreased blood lymphocyte counts. **E.** Presence rate of *Collinsella*
 567 *sp 4_8_47FAA* dSV (927-928 kb) showed difference between the presence and absence
 568 of heart rhythm problems.

569




570 **Figure 6. Association of microbial temporal changes with plasma metabolite**
 571 **changes. A.** Summary of microbial associations to plasma metabolites. A total of 455
 572 associations were not only significant at FDR<0.05 for the joint association analysis,
 573 but also significant at P<0.05 for the association analysis of temporal changes, with the
 574 same effect direction of both analyses. These include 273 associations to species and
 575 pathway abundances and 182 associations to microbial SVs. **B.** A positive association
 576 between thiamine and *Alistipes senegalensis* abundance changes. **C.** The positive
 577 association between microbial-derived uremic toxin p-cresol sulfate and *Bacteroidales*
 578 *bacterium* abundance changes. **D.** Variability changes in multiple vSVs of *Blautia*
 579 *wexlerae* associated with microbial driven uremic toxins.



580
 581 **Figure 7. Casual mediation linkages among the gut microbiome, metabolites and**
 582 **phenotypes. A.** 29 micorbial features associated with not only human phenotypes but
 583 also plasma metabolites. **B.** 21 significant mediation linkages. **C.** Microbial sulfate
 584 reduction pathway casually contributed to diastolic blood pressure through thiamine. **D.**
 585 Microbial lipopolysaccharides pathway casually contributed to systolic blood pressure

586 through AFMK. **E.** Ruminococcus sp vSV (300-305 kb) casually contributed to plasma
 587 LDL through tyrosol 4-sulfate.



588

589 **Figure 8. Long-term changes in antibiotic resistance genes and virulence factors.**

590 **A.** The total load of microbial antibiotic resistance genes increased between the two
 591 time points four years apart. **B.** The number of microbial virulence genes decreased
 592 over this time period. **C.** Positive associations between microbial species abundance
 593 changes and antibiotic resistance gene abundance changes. Red dots represent
 594 antibiotic resistance categories while blue dots indicate microbial species. **D.** Meat
 595 frequency positively associated with microbial aminoglycoside resistance gene
 596 abundance changes. **E.** Meat intake positively associated with microbial lincosamide
 597 resistance gene abundance changes.

599 **STAR ★ METHODS**600 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Biological Samples		
Fecal samples	This study	
Blood samples	This study	
Critical Commercial Assays		
AllPrep DNA/RNA Mini Kit	QIAGEN	80204
Quant-iT PicoGreen dsDNA Assay	Life Technologies	P7589
Blood Assays	Lifelines Biobank	https://www.lifelines.nl
Software and Algorithms		
R (version 3.6.0)	R Foundation	http://www.r-project.org/
Python (version 2.7.11)	Python	https://www.python.org
KneadData (version 0.4.6.1)	The Huttenhower Lab	https://huttenhower.sph.harvard.edu/kneaddata
Bowtie2 (version 2.1.0)	(Langmead et al., 2019)	http://bowtie-bio.sourceforge.net/bowtie2
MetaPhlan2 (version 2.7.2)	(Truong et al., 2015)	https://huttenhower.sph.harvard.edu/metaphlan
HUMAnN2 (version 0.10.0)	(Franzosa et al., 2018)	https://huttenhower.sph.harvard.edu/humann
ShortBRED (version 0.9.5)	(Kaminski et al., 2015)	https://huttenhower.sph.harvard.edu/shortbred
StrainPhlAn (version 1.2.0)	(Truong et al., 2017)	http://segatalab.cibio.unitn.it/tools/strainphlan
ICRA	(Zeevi et al., 2019)	https://github.com/segalab/SGVFinder
SGVFinder	(Zeevi et al., 2019)	https://github.com/segalab/SGVFinder
Deposited Data		
LLD raw metagenomics	EGA	https://www.ebi.ac.uk
HMP raw metagenomics	HMP	https://www.hmpdacc.org

601 **CONTACT FOR REAGENT AND RESOURCE SHARING**

602 Further information and requests for resources and reagents should be directed to the

603 Lead Contact, Jingyuan Fu (j.fu@umcg.nl).604 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

605 **Study cohort**

606 The LifeLines-DEEP cohort is a sub-cohort of the LifeLines biobank (167,729
607 participants) (Scholtens et al., 2015) that involved 1,539 participants and is being used
608 to assess the biomedical, socio-demographic, behavioral, physical, and psychological
609 factors that contribute to health and disease from the north of the Netherlands
610 (Tigchelaar et al., 2015; Wijmenga and Zhernakova, 2018). The study has been
611 approved by Institutional ethics review board (IRB) of University Medical Center
612 Groningen (ref. M12.113965). This cohort has now been followed-up, and detailed
613 phenotypic data was collected at two time points around four years apart. Of the 1,135
614 individuals for whom we generated metagenomics sequencing data in 2013
615 (Zhernakova et al., 2016), follow-up stool samples were collected for 338 individuals
616 (55.6% female and 44.4% male) at the second time point. The duration between two
617 time points ranged from 3.33 to 3.92 years (mean=3.53, sd=0.12). At baseline, the mean
618 age of participants was 48.2 years (18-80, sd=11.7) and their mean BMI was 25.4 (17.6-
619 43.3, sd=4.08). For the follow-up, the mean age was 51.7 years (22-84, sd=11.7) and
620 the mean BMI was 25.6 (16.1-37.6, sd=4.0). Phenotypic data assessed in the present
621 study included 10 intrinsic factors (e.g. age, gender, BMI, height, smoking), 9 blood
622 cell counts, 7 plasma metabolites (e.g. glucose, cholesterol, triglycerides) and 39
623 medications (e.g. PPI, oral contraceptives, beta blockers, statins).

624 **METHOD DETAILS**

625 **Metagenomic data generation and preprocessing**

626 Stool sample collection and processing at both time points followed the same protocol.
627 All participants were asked to collect fecal samples at home and place them in their
628 home freezer (-20°C) within 15 minutes after production. Subsequently, a nurse visited
629 the participant to pick up the fecal samples on dry ice and transfer them to the laboratory.
630 Aliquots were then made and stored at -80°C until further processing. The same
631 protocol for fecal DNA isolation and metagenomics sequencing was used at both time
632 points. Fecal DNA isolation was performed using the AllPrep DNA/RNA Mini Kit

633 (Qiagen; cat. 80204). After DNA extraction, fecal DNA was sent to the Broad Institute
634 of Harvard and MIT in Cambridge, Massachusetts, USA, where library preparation and
635 whole genome shotgun sequencing were performed on the Illumina HiSeq platform.
636 From the raw metagenomic sequencing data, low-quality reads were discarded by the
637 sequencing facility and reads belonging to the human genome were removed by
638 mapping the data to the human reference genome (version NCBI37) with KneadData
639 (version 0.4.6.1) Bowtie2 (version 2.1.0) (Langmead et al., 2019). The read depths of
640 all samples at both time points were very comparable (paired Wilcoxon test $P=0.89$).

641 **Taxonomic profiles**

642 Microbial taxonomic profiles were generated using MetaPhlAn2 (version 2.7.2)
643 (Truong et al., 2015). MetaPhlAn2 relies on nearly 1 million unique clade-specific
644 marker genes identified from around 17,000 reference genomes (13,500 bacterial and
645 archaeal, 3,500 viral and 110 eukaryotic), allowing unambiguous taxonomic
646 assignments, accurate estimation of organismal relative abundance and species-level
647 resolution for bacteria, archaea, eukaryotes and viruses. Microbial species present in
648 more than 10% of the samples were included for further analyses. This yielded a list of
649 157 species that account for 97.81% of taxonomic composition.

650 **Functional profiles**

651 Microbial functional profiles were determined using HUMAnN2 (version 0.10.0)
652 (Franzosa et al., 2018), which maps DNA/RNA reads to a customized database of
653 functionally annotated pan-genomes. HUMAnN2 reported the abundances of gene
654 families from the UniProt Reference Clusters (Bateman et al., 2015) (UniRef90), which
655 were further mapped to microbial pathways from the MetaCyc metabolic pathway
656 database (Caspi et al., 2016; Caspi et al., 2018). Based on MetaPhlAn2, HUMAnN2
657 can further characterize community functional profiles stratified by known (species-
658 level) and unclassified organisms. In total, 343 microbial pathways present in more than
659 10% of the samples were kept for subsequent analysis, accounting for 99.98% of

660 microbial functional composition.

661 **Antibiotic resistance genes**

662 Quantification of antibiotic resistance genes in metagenomics was performed using
663 shortBRED (version 0.9.5) (Kaminski et al., 2015) with markers generated from the
664 ResFinder database, which reports more than 1,800 different antimicrobial resistance
665 genes (November 2018 version) (Zankari et al., 2012). In brief, ShortBRED is a
666 pipeline to take a set of protein sequences from a target database (i.e. ResFinder), cluster
667 them into families, build consensus sequences to represent the families, and then reduce
668 these consensus sequences to a set of unique identifying strings (markers). The pipeline
669 then searches for these markers in metagenomic data and determines the presence and
670 abundance of the protein families of interest. We classified the abundance of 29
671 antibiotic resistance genes that were present in at least 10% of the samples.

672 **Virulence genes**

673 We also searched the metagenomic data for bacterial virulence genes using shortBRED
674 (version 0.9.5) (Kaminski et al., 2015) and markers generated from virulence factors of
675 pathogenic bacteria database (VFDB, core dataset of DNA sequences, version:
676 November, 2018) (Liu et al., 2019). Here we classified the abundance of 59 virulence
677 genes that are present in at least 10% of the samples.

678 **Strain level SNP haplotypes**

679 Strain SNP haplotypes were generated using StrainPhlAn1 (version 1.2.0) (Truong et
680 al., 2017). This method is based on reconstructing consensus sequence variants within
681 species-specific marker genes and using them to estimate strain-level phylogenies.
682 Reconstructed markers with a percentage of ambiguous bases >20% are discarded.
683 Consensus sequences are then trimmed by removing the first and last 50 bases because
684 the terminal positions have lower coverages due to the limitations in mapping reads
685 against truncated sequences (Truong et al., 2017). Next, clades with a percentage of
686 markers <50% are removed, and if the percentage of samples in which a marker is

687 present is <50%, that marker is also removed. Samples with full sequences
688 concatenated from all markers and a percentage of gaps >50% are removed from the
689 alignment. Finally, we used the multiple sequence alignment file to generate a
690 phylogenetic distance matrix that contains the pairwise nucleotide substitution rate
691 between strains by applying the Kimura 2-parameter method from the EMBOSS
692 package (Rice et al., 2000). Using this method, we classified the within-individual SNP
693 haplotype difference of the dominant strain in 37 species that present in at least 5 sample
694 pairs, and 18 of these were obtained in at least 10% of sample pairs.

695 **Structural variants in microbial genome**

696 We applied SGV-Finder pipeline (Zeevi et al., 2019) to classify SVs that are either
697 completely absent in microbial genome of some samples (deletion SVs, dSVs) or those
698 whose coverage is highly variable across samples (variable SVs, vSVs). Prior to SV
699 classification, an 'iterative coverage-based read assignment' algorithm was applied that
700 resolves ambiguous read assignments to regions that are similar between different
701 bacteria, using information on bacterial relative abundances in the microbiome, their
702 genomic sequencing coverage and sequencing and alignment qualities (Zeevi et al.,
703 2019). In total, we classified 6,130 SVs, including 4,333 dSVs and 1,797 vSVs from
704 41 microbial species that present in at least 5 sample pairs. The SVs of 26 species can
705 be obtained in at least 10% of sample pairs. We further calculated Canberra distance
706 between individuals based on dSVs and vSVs of each microbial species, respectively.

707 **Plasma untargeted metabolomics**

708 Plasma samples of study participants were collected and frozen at -80°C with EDTA.
709 During extraction, plasma samples were thawed on ice, vortexed, and spun down. 20µL
710 of plasma was combined with 180µL of 80% methanol and vortexed for 15 seconds.
711 The samples were incubated at 4°C for one hour to precipitate proteins, and then spun
712 for 30 minutes at 3,200 RCF. 100µL of supernatant was removed and used for Flow-
713 Injection Time-of-Flight Mass Spectrometry (FIA-TOF) analysis in General

714 Metabolics, Inc., Boston, USA, by using protocols described previously (Fuhrer et al.,
715 2011). In total, 1183 metabolites with annotations were involved in the analysis. The
716 annotated metabolites cover 18 chemical categories based on Human Metabolome
717 Database (HMDB) (**Table S2a**) (Wishart et al., 2018). The characterization of plasma
718 protein-bound uremic toxins, including indoxyl sulfate, p-cresyl sulfate, phenyl sulfate,
719 phenylacetic acid and hippuric acid was based on (Wang and Zhao, 2018).

720 **QUANTIFICATION AND STATISTICAL ANALYSIS**

721 **Principal coordinates analysis (PCoA)**

722 The relative abundances of all microbial species and pathways were included in PCoA.
723 We applied the *vegdist()* function from the *vegan* (version 2.5.5) R package to calculate
724 the Bray-Curtis dissimilarity matrix. Subsequently, classical metric multidimensional
725 scaling was carried out based on the Bray-Curtis distance matrix to obtain different
726 principal coordinates.

727 **Comparison of microbial composition dissimilarity**

728 To compare the differences in overall microbial species and pathway compositions
729 between- and within-individuals, we applied a Wilcoxon test on Bray-Curtis
730 dissimilarity. Since the number of dissimilarities between- and within-individuals was
731 unbalanced, we calculated an empiric P-value by permuting samples of microbial
732 species and pathway relative abundance tables for 10,000 times.

733 **Differential microbiome feature abundance**

734 We applied different transformation/normalization methods for the different microbial
735 abundance datasets, i.e. centered log-ratio transformation for relative abundances (sum
736 up to 1) of microbial species and functional pathways and log transformation (with
737 pseudo count of 1 for zero values) for microbial antibiotic resistance and virulence gene
738 abundance. Within-individual differences in microbial abundance were then assessed
739 by using paired Wilcoxon tests. The false discovery rate (FDR) was calculated with
740 1,000 times permutation.

741 **Distance matrix-based individual classification**

742 We evaluated if microbial abundance and genome information can be used for
743 individual classification (i.e. to identify if two samples belong to the same individual).
744 To do so, we generated Bray-Curtis distances based on microbial species and pathway
745 relative abundance, Kimura distance based on SNP haplotype profile and Canberra
746 distance based on SV profiles. The samples were clustered using single-linkage
747 clustering, also known as nearest neighbor clustering. If two samples, and only those
748 two samples, from the same individual were clustered together as the closest neighbor,
749 we considered that they were classified correctly. We then defined the accuracy by
750 calculating the proportion of the total number of correctly classified pairs. Finally, by
751 establishing a specific cutoff, we could determine whether a pair of samples come from
752 the same individual by their dissimilarity, and the cutoff affects the performance of
753 classifier. A receiver operating characteristic curve (ROC) was drawn based on
754 dissimilarity to reflect the specificity and sensitivity of classification using *roc()*
755 function from *pROC* (version 1.16.1) (Robin et al., 2011).

756 **Stepwise distance matrices combination**

757 A total of 71 distance matrices were present in more than 10% of sample pairs,
758 including 69 genetic distance matrices (SNP haplotype distance matrices for 18 species,
759 dSV and vSV distance matrices for 26 species) and 2 compositional distance matrices
760 generated by microbial species and pathways abundance. We aimed to see whether we
761 can utilize these genetic and microbial distance matrices to classify different samples
762 from the same individuals. Each of these distance matrices was considered as one
763 classifier. We carried out a stepwise forward selection approach to combine multiple
764 microbial genetic and compositional distance matrices. The cohort was randomly
765 divided into a discovery set with 60% of sample pairs and a validation set with 40% of
766 pairs. In order to combine multiple distance matrices, we first standardized and scaled
767 all distance matrices between 0 and 1 by dividing each matrix by its largest value. In
768 the discovery set, we assessed the accuracy of each distance matrix in classifying

769 samples as described above. We started with the distance matrix that had the highest
770 accuracy, i.e. the 1st classifier. We then moved on to the model with two distance
771 matrices by adding another distance matrix and taking the mean value of two matrices.
772 We tested all possible combinations and chose the combination with the highest
773 accuracy. The classifier included at the second step was considered as the 2nd classifier.
774 This step was repeated to include the 3rd classifier, and this process continued until all
775 the distance matrices were included. In this way, we generated a series of models that
776 included different number of distance matrices and tested their performance in the
777 validation set. The whole procedure of dataset splitting and feature combination was
778 repeated 10 times, and we determined the optimal feature number N at which the
779 performance did not improve anymore when more matrices were added. The distance-
780 based features were prioritized by their median ranks across 10-times feature selections,
781 then top- N distance matrices were selected as the optimum combination for the final
782 classifier.

783 **Microbial associations to host phenotypes and metabolites**

784 We first established microbial associations to host phenotypes and metabolites (**Table**
785 **S1**) using linear and logistic mixed-effects model (joint associations): dependent
786 variable \sim (intercept) + independent variable + age + sex + (1| time point) + (1| subject),
787 for continuous and binary microbial traits, respectively. We further validated these joint
788 associations by linking microbial changes to host phenotypic and metabolic changes
789 with a regression model (delta associations): dependent variable changes \sim (intercept)
790 + independent variable changes + age + sex, for continuous and binary microbial traits
791 (dSVs), respectively. The Benjamini-Hochberg procedure was applied to control FDR
792 (Benjamini et al., 2001).

793 **Casual mediation linkage inference**

794 For phenotypic and metabolic associations to the same microbial feature, we first
795 checked whether human the phenotype associated with the metabolite by using both

796 joint and delat association models as described above. Next, bi-directional medication
797 analysis was carried out by using *mediate* function from mediation (version 4.5.0) R
798 package to inference casual role of microbiome in contributing to human phenotype
799 through metabolite. The Benjamini-Hochberg procedure was applied to control FDR.

800 **DATA AND SOFTWARE AVAILABILITY**

801 The raw metagenomic sequencing data of the Lifelines-DEEP and replication cohorts
802 are available from the European Genome-Phenome Archive (EGA,
803 <https://www.ebi.ac.uk/ega/home>) via accession number EGAS00001001704, and
804 Human Microbiome Project website (<https://www.hmpdacc.org>), respectively.

805 Analysis codes are available via: [https://github.com/GRONINGEN-MICROBIOME-](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/LLDeep_microbiome_5year_follow-up)
806 [CENTRE/Groningen-](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/LLDeep_microbiome_5year_follow-up)
807 [Microbiome/tree/master/Projects/LLDeep_microbiome_5year_follow-up](https://github.com/GRONINGEN-MICROBIOME-CENTRE/Groningen-Microbiome/tree/master/Projects/LLDeep_microbiome_5year_follow-up)

808 **REFERENCES**

- 809 Aguilar-Barajas, E., Diaz-Perez, C., Ramirez-Diaz, M.I., Riveros-Rosas, H., and Cervantes, C.
810 (2011). Bacterial transport of sulfate, molybdate, and related oxyanions. *Biometals* 24, 687-707.
- 811 Alaei-Shahmiri, F., Soares, M.J., Zhao, Y., and Sherriff, J. (2015). The impact of thiamine
812 supplementation on blood pressure, serum lipids and C-reactive protein in individuals with
813 hyperglycemia: a randomised, double-blind cross-over trial. *Diabetes Metab Syndr* 9, 213-217.
- 814 Aslam, B., Wang, W., Arshad, M.I., Khurshid, M., Muzammil, S., Rasool, M.H., Nisar, M.A.,
815 Alvi, R.F., Aslam, M.A., Qamar, M.U., *et al.* (2018). Antibiotic resistance: a rundown of a
816 global crisis. *Infect Drug Resist* 11, 1645-1658.
- 817 Bateman, A., Martin, M.J., O'Donovan, C., Magrane, M., Apweiler, R., Alpi, E., Antunes, R.,
818 Ar-Ganiska, J., Bely, B., Bingley, M., *et al.* (2015). UniProt: a hub for protein information.
819 *Nucleic Acids Res* 43, D204-D212.
- 820 Begley, T.P. (1996). The biosynthesis and degradation of thiamin (vitamin B1). *Nat Prod Rep*
821 13, 177-185.
- 822 Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N., and Golani, I. (2001). Controlling the false
823 discovery rate in behavior genetics research. *Behav Brain Res* 125, 279-284.
- 824 Caspi, R., Billington, R., Ferrer, L., Foerster, H., Fulcher, C.A., Keseler, I.M., Kothari, A.,
825 Krummenacker, M., Latendresse, M., Mueller, L.A., *et al.* (2016). The MetaCyc database of
826 metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases.
827 *Nucleic Acids Res* 44, D471-D480.
- 828 Caspi, R., Billington, R., Fulcher, C.A., Keseler, I.M., Kothari, A., Krummenacker, M.,
829 Latendresse, M., Midford, P.E., Ong, Q., Ong, W.K., *et al.* (2018). The MetaCyc database of
830 metabolic pathways and enzymes. *Nucleic Acids Res* 46, D633-D639.
- 831 Chen, L., Collij, V., Jaeger, M., van den Munckhof, I.C.L., Vich Vila, A., Kurilshikov, A.,
832 Gacesa, R., Sinha, T., Oosting, M., Joosten, L.A.B., *et al.* (2020a). Gut microbial co-abundance
833 networks show specificity in inflammatory bowel disease and obesity. *Nature Communications*
834 11, 4018.
- 835 Chen, L., Garmaeva, S., Zhernakova, A., Fu, J., and Wijmenga, C. (2018). A system biology
836 perspective on environment-host-microbe interactions. *Hum Mol Genet* 27, R187-R194.
- 837 Chen, L., van den Munckhof, I.C.L., Schraa, K., Ter Horst, R., Koehorst, M., van Faassen, M.,
838 van der Ley, C., Doestzada, M., Zhernakova, D.V., Kurilshikov, A., *et al.* (2020b). Genetic and
839 Microbial Associations to Plasma and Fecal Bile Acids in Obesity Relate to Plasma Lipids and
840 Liver Fat Content. *Cell Rep* 33, 108212.
- 841 Coyte, K.Z., Schluter, J., and Foster, K.R. (2015). The ecology of the microbiome: Networks,
842 competition, and stability. *Science* 350, 663-666.
- 843 DiNicolantonio, J.J., Niazi, A.K., Lavie, C.J., O'Keefe, J.H., and Ventura, H.O. (2013).
844 Thiamine supplementation for the treatment of heart failure: a review of the literature. *Congest*
845 *Heart Fail* 19, 214-222.
- 846 Duranton, F., Cohen, G., De Smet, R., Rodriguez, M., Jankowski, J., Vanholder, R., Argiles, A.,
847 and European Uremic Toxin Work, G. (2012). Normal and pathologic concentrations of uremic
848 toxins. *J Am Soc Nephrol* 23, 1258-1270.
- 849 Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J.P., Druart, C., Bindels, L.B., Guiot, Y., Derrien,

850 M., Muccioli, G.G., Delzenne, N.M., *et al.* (2013). Cross-talk between Akkermansia
851 muciniphila and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A*
852 *110*, 9066-9071.

853 Faith, J.J., Guruge, J.L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A.L.,
854 Clemente, J.C., Knight, R., Heath, A.C., Leibel, R.L., *et al.* (2013). The long-term stability of
855 the human gut microbiota. *Science* *341*, 1-8.

856 Falony, G., Joossens, M., Vieira-Silva, S., Wang, J., Darzi, Y., Faust, K., Kurilshikov, A., Bonder,
857 M.J., Valles-Colomer, M., Vandeputte, D., *et al.* (2016). Population-level analysis of gut
858 microbiome variation. *Science* *352*, 560-564.

859 Franzosa, E.A., Huang, K., Meadow, J.F., Gevers, D., Lemon, K.P., Bohannon, B.J., and
860 Huttenhower, C. (2015). Identifying personal microbiomes using metagenomic codes. *Proc*
861 *Natl Acad Sci U S A* *112*, E2930-2938.

862 Franzosa, E.A., McIver, L.J., Rahnard, G., Thompson, L.R., Schirmer, M., Weingart, G.,
863 Lipson, K.S., Knight, R., Caporaso, J.G., Segata, N., *et al.* (2018). Species-level functional
864 profiling of metagenomes and metatranscriptomes. *Nature Methods* *15*, 962-968.

865 Fuhrer, T., Heer, D., Begemann, B., and Zamboni, N. (2011). High-Throughput, Accurate Mass
866 Metabolome Profiling of Cellular Extracts by Flow Injection - Time-of-Flight Mass
867 Spectrometry. *Analytical Chemistry* *83*, 7074-7080.

868 Garud, N.R., Good, B.H., Hallatschek, O., and Pollard, K.S. (2019). Evolutionary dynamics of
869 bacteria in the gut microbiome within and across hosts. *PLoS Biol* *17*, e3000102.

870 Greenblum, S., Carr, R., and Borenstein, E. (2015). Extensive strain-level copy-number
871 variation across human gut microbiome species. *Cell* *160*, 583-594.

872 Havelaar, A.H., Graveland, H., van de Kasstele, J., Zomer, T.P., Veldman, K., and Bouwknegt,
873 M. (2017). A summary index for antimicrobial resistance in food animals in the Netherlands.
874 *BMC Vet Res* *13*, 305.

875 Hornef, M.W., and Pabst, O. (2016). Real friends: Faecalibacterium prausnitzii supports
876 mucosal immune homeostasis. *Gut* *65*, 365-367.

877 Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., Vandamme,
878 P., and Vermeire, S. (2011). Dysbiosis of the faecal microbiota in patients with Crohn's disease
879 and their unaffected relatives. *Gut* *60*, 631-637.

880 Kaminski, J., Gibson, M.K., Franzosa, E.A., Segata, N., Dantas, G., and Huttenhower, C.
881 (2015). High-Specificity Targeted Functional Profiling in Microbial Communities with
882 ShortBRED. *PLoS Comput Biol* *11*, e1004557.

883 Kikuchi, K., Saigusa, D., Kanemitsu, Y., Matsumoto, Y., Thanai, P., Suzuki, N., Mise, K.,
884 Yamaguchi, H., Nakamura, T., Asaji, K., *et al.* (2019). Gut microbiome-derived phenyl sulfate
885 contributes to albuminuria in diabetic kidney disease. *Nat Commun* *10*, 1835.

886 Langmead, B., Wilks, C., Antonescu, V., and Charles, R. (2019). Scaling read aligners to
887 hundreds of threads on general-purpose processors. *Bioinformatics* *35*, 421-432.

888 Liu, B., Zheng, D., Jin, Q., Chen, L., and Yang, J. (2019). VFDB 2019: a comparative
889 pathogenomic platform with an interactive web interface. *Nucleic Acids Res* *47*, D687-D692.

890 Lloyd-Price, J., Arze, C., Ananthakrishnan, A.N., Schirmer, M., Avila-Pacheco, J., Poon, T.W.,
891 Andrews, E., Ajami, N.J., Bonham, K.S., Brislawn, C.J., *et al.* (2019). Multi-omics of the gut

892 microbial ecosystem in inflammatory bowel diseases. *Nature* 569, 655-662.

893 Lloyd-Price, J., Mahurkar, A., Rahnavard, G., Crabtree, J., Orvis, J., Hall, A.B., Brady, A.,
894 Creasy, H.H., McCracken, C., Giglio, M.G., *et al.* (2017). Strains, functions and dynamics in
895 the expanded Human Microbiome Project. *Nature* 550, 61-66.

896 Mayo, J.C., Sainz, R.M., Tan, D.X., Hardeland, R., Leon, J., Rodriguez, C., and Reiter, R.J.
897 (2005). Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-
898 methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages.
899 *J Neuroimmunol* 165, 139-149.

900 Mehta, R.S., Abu-Ali, G.S., Drew, D.A., Lloyd-Price, J., Subramanian, A., Lochhead, P., Joshi,
901 A.D., Ivey, K.L., Khalili, H., Brown, G.T., *et al.* (2018). Stability of the human faecal
902 microbiome in a cohort of adult men. *Nat Microbiol* 3, 347-355.

903 Miquel, S., Martin, R., Rossi, O., Bermudez-Humaran, L.G., Chatel, J.M., Sokol, H., Thomas,
904 M., Wells, J.M., and Langella, P. (2013). *Faecalibacterium prausnitzii* and human intestinal
905 health. *Curr Opin Microbiol* 16, 255-261.

906 Mishra, A.K., Gimenez, G., Lagier, J.C., Robert, C., Raoult, D., and Fournier, P.E. (2012).
907 Genome sequence and description of *Alistipes senegalensis* sp. nov. *Stand Genomic Sci* 6, 1-
908 16.

909 Munukka, E., Rintala, A., Toivonen, R., Nylund, M., Yang, B., Takanen, A., Hanninen, A.,
910 Vuopio, J., Huovinen, P., Jalkanen, S., *et al.* (2017). *Faecalibacterium prausnitzii* treatment
911 improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice. *ISME J*
912 11, 1667-1679.

913 Ochman, H., Lawrence, J.G., and Groisman, E.A. (2000). Lateral gene transfer and the nature
914 of bacterial innovation. *Nature* 405, 299-304.

915 Ray, D., Alpini, G., and Glaser, S. (2014). Probiotic *Bifidobacterium* species: potential
916 beneficial effects in diarrheal disorders. Focus on "Probiotic *Bifidobacterium* species stimulate
917 human SLC26A3 gene function and expression in intestinal epithelial cells". *Am J Physiol Cell*
918 *Physiol* 307, C1081-1083.

919 Rezzani, R., Porteri, E., De Ciuceis, C., Bonomini, F., Rodella, L.F., Paiardi, S., Boari, G.E.,
920 Platto, C., Pilu, A., Avanzi, D., *et al.* (2010). Effects of melatonin and Pycnogenol on small
921 artery structure and function in spontaneously hypertensive rats. *Hypertension* 55, 1373-1380.

922 Rice, P., Longden, I., and Bleasby, A. (2000). EMBOSS: the European Molecular Biology Open
923 Software Suite. *Trends Genet* 16, 276-277.

924 Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.C., and Muller, M. (2011).
925 pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC*
926 *Bioinformatics* 12, 77.

927 Rothschild, D., Weissbrod, O., Barkan, E., Kurilshikov, A., Korem, T., Zeevi, D., Costea, P.I.,
928 Godneva, A., Kalka, I.N., Bar, N., *et al.* (2018). Environment dominates over host genetics in
929 shaping human gut microbiota. *Nature* 555, 210-215.

930 Schloissnig, S., Arumugam, M., Sunagawa, S., Mitreva, M., Tap, J., Zhu, A., Waller, A., Mende,
931 D.R., Kultima, J.R., Martin, J., *et al.* (2013). Genomic variation landscape of the human gut
932 microbiome. *Nature* 493, 45-50.

933 Scholtens, S., Smidt, N., Swertz, M.A., Bakker, S.J., Dotinga, A., Vonk, J.M., van Dijk, F., van

934 Zon, S.K., Wijmenga, C., Wolffenbuttel, B.H., *et al.* (2015). Cohort Profile: LifeLines, a three-
935 generation cohort study and biobank. *Int J Epidemiol* *44*, 1172-1180.

936 Silva, S.O., Rodrigues, M.R., Carvalho, S.R., Catalani, L.H., Campa, A., and Ximenes, V.F.
937 (2004). Oxidation of melatonin and its catabolites, N1-acetyl-N2 -formyl-5-
938 methoxykynuramine and N1-acetyl-5-methoxykynuramine, by activated leukocytes. *J Pineal*
939 *Res* *37*, 171-175.

940 Solomon, S.D., Uno, H., Lewis, E.F., Eckardt, K.U., Lin, J., Burdmann, E.A., de Zeeuw, D.,
941 Ivanovich, P., Levey, A.S., Parfrey, P., *et al.* (2010). Erythropoietic response and outcomes in
942 kidney disease and type 2 diabetes. *N Engl J Med* *363*, 1146-1155.

943 Stewart, C.J., Ajami, N.J., O'Brien, J.L., Hutchinson, D.S., Smith, D.P., Wong, M.C., Ross,
944 M.C., Lloyd, R.E., Doddapaneni, H., Metcalf, G.A., *et al.* (2018). Temporal development of
945 the gut microbiome in early childhood from the TEDDY study. *Nature* *562*, 583-588.

946 Tigchelaar, E.F., Zhernakova, A., Dekens, J.A., Hermes, G., Baranska, A., Mujagic, Z., Swertz,
947 M.A., Munoz, A.M., Deelen, P., Cenit, M.C., *et al.* (2015). Cohort profile: LifeLines DEEP, a
948 prospective, general population cohort study in the northern Netherlands: study design and
949 baseline characteristics. *BMJ Open* *5*, e006772.

950 Truong, D.T., Franzosa, E.A., Tickle, T.L., Scholz, M., Weingart, G., Pasolli, E., Tett, A.,
951 Huttenhower, C., and Segata, N. (2015). MetaPhlan2 for enhanced metagenomic taxonomic
952 profiling. *Nat Methods* *12*, 902-903.

953 Truong, D.T., Tett, A., Pasolli, E., Huttenhower, C., and Segata, N. (2017). Microbial strain-
954 level population structure and genetic diversity from metagenomes. *Genome Res* *27*, 626-638.

955 Vacca, I. (2017). Biofilms: New ways for streptococci to settle down. *Nat Rev Microbiol* *15*,
956 321.

957 Vatanen, T., Franzosa, E.A., Schwager, R., Tripathi, S., Arthur, T.D., Vehik, K., Lernmark, A.,
958 Hagopian, W.A., Rewers, M.J., She, J.X., *et al.* (2018). The human gut microbiome in early-
959 onset type 1 diabetes from the TEDDY study. *Nature* *562*, 589-594.

960 Vatanen, T., Plichta, D.R., Somani, J., Munch, P.C., Arthur, T.D., Hall, A.B., Rudolf, S., Oakeley,
961 E.J., Ke, X., Young, R.A., *et al.* (2019). Genomic variation and strain-specific functional
962 adaptation in the human gut microbiome during early life. *Nat Microbiol* *4*, 470-479.

963 Veloo, A.C.M., Baas, W.H., Haan, F.J., Coco, J., and Rossen, J.W. (2019). Prevalence of
964 antimicrobial resistance genes in *Bacteroides* spp. and *Prevotella* spp. Dutch clinical isolates.
965 *Clin Microbiol Infect* *25*, 9-13.

966 Vich Vila, A., Imhann, F., Collij, V., Jankipersadsing, S.A., Gurry, T., Mujagic, Z., Kurilshikov,
967 A., Bonder, M.J., Jiang, X., Tigchelaar, E.F., *et al.* (2018). Gut microbiota composition and
968 functional changes in inflammatory bowel disease and irritable bowel syndrome. *Sci Transl*
969 *Med* *10*, eaap8914.

970 Vieira-Silva, S., Falony, G., Belda, E., Nielsen, T., Aron-Wisnewsky, J., Chakaroun, R.,
971 Forslund, S.K., Assmann, K., Valles-Colomer, M., Nguyen, T.T.D., *et al.* (2020). Statin therapy
972 is associated with lower prevalence of gut microbiota dysbiosis. *Nature* *581*, 310-315.

973 Wang, Z., and Zhao, Y. (2018). Gut microbiota derived metabolites in cardiovascular health
974 and disease. *Protein Cell* *9*, 416-431.

975 Wijmenga, C., and Zhernakova, A. (2018). The importance of cohort studies in the post-GWAS

976 era. *Nat Genet*, 322-328.

977 Wishart, D.S., Feunang, Y.D., Marcu, A., Guo, A.C., Liang, K., Vazquez-Fresno, R., Sajed, T.,
978 Johnson, D., Li, C., Karu, N., *et al.* (2018). HMDB 4.0: the human metabolome database for
979 2018. *Nucleic Acids Res* 46, D608-D617.

980 Yassour, M., Jason, E., Hogstrom, L.J., Arthur, T.D., Tripathi, S., Siljander, H., Selvenius, J.,
981 Oikarinen, S., Hyoty, H., Virtanen, S.M., *et al.* (2018). Strain-Level Analysis of Mother-to-
982 Child Bacterial Transmission during the First Few Months of Life. *Cell Host Microbe* 24, 146-
983 154.

984 Yu, T.-H., Tang, W.-H., Lu, Y.-C., Wang, C.-P., Hung, W.-C., Wu, C.-C., Tsai, I.-T., Chung, F.-
985 M., Houn, J.-Y., and Lan, W.-C. (2018). Association between hippuric acid and left ventricular
986 hypertrophy in maintenance hemodialysis patients. *Clinica Chimica Acta* 484, 47-51.

987 Zankari, E., Hasman, H., Cosentino, S., Vestergaard, M., Rasmussen, S., Lund, O., Aarestrup,
988 F.M., and Larsen, M.V. (2012). Identification of acquired antimicrobial resistance genes. *J*
989 *Antimicrob Chemother* 67, 2640-2644.

990 Zeevi, D., Korem, T., Godneva, A., Bar, N., Kurilshikov, A., Lotan-Pompan, M., Weinberger,
991 A., Fu, J., Wijmenga, C., Zhernakova, A., *et al.* (2019). Structural variation in the gut
992 microbiome associates with host health. *Nature* 568, 43-48.

993 Zhao, H., Shen, J., Djukovic, D., Daniel-MacDougall, C., Gu, H., Wu, X., and Chow, W.H.
994 (2016). Metabolomics-identified metabolites associated with body mass index and prospective
995 weight gain among Mexican American women. *Obes Sci Pract* 2, 309-317.

996 Zhernakova, A., Kurilshikov, A., Bonder, M.J., Tigchelaar, E.F., Schirmer, M., Vatanen, T.,
997 Mujagic, Z., Vila, A.V., Falony, G., Vieira-Silva, S., *et al.* (2016). Population-based
998 metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science*
999 352, 565-569.

1000 Zhou, W., Sailani, M.R., Contrepois, K., Zhou, Y., Ahadi, S., Leopold, S.R., Zhang, M.J., Rao,
1001 V., Avina, M., Mishra, T., *et al.* (2019). Longitudinal multi-omics of host-microbe dynamics in
1002 prediabetes. *Nature* 569, 663-671.

1003